Real-World Evaluation of Mepolizumab in Severe Asthma
Research type
Research Study
Full title
A prospective, real-world, interventional study to evaluate the effect of mepolizumab on achieving clinical remission in participants with severe asthma
IRAS ID
337926
Contact name
Rikkita Unadkat
Contact email
Sponsor organisation
GlaxoSmithKline Research & Development Limited
Duration of Study in the UK
2 years, 6 months, 24 days
Research summary
This multi-centre, global study is being undertaken to better understand how well the medication mepolizumab (NUCALA) works in routine medical practice to treat a sub-population of adult patients with severe asthma who have what is termed an eosinophilic phenotype. Eosinophils are a type of inflammatory white blood cell.
Mepolizumab will not be provided as part of this study; individuals will be asked to participate in this study because they have already been prescribed mepolizumab. All data collected is related to the participant’s experience while on mepolizumab prescribed by their doctor as part of their routine medical care.
Once a participant has been confirmed eligible to participate, and has provided their written informed consent, they will come to the clinic for their regular scheduled visits as decided with their doctor, and also at specified timepoints (6 months, 12 months, and 24 months after enrolment). At visits, participants will be asked to complete a range of questionnaires about their asthma and its impact on their daily life as well as, at some visits, breathing tests by blowing into equipment to measure lung function (spirometry). Participation in the study does not require any additional blood samples other than those required in the normal course of the participant’s regular care.
Approximately 336 people will take part in this study across a number of countries. It will take up to 24 months to complete the study.
REC name
London - Brent Research Ethics Committee
REC reference
24/PR/0127
Date of REC Opinion
13 Feb 2024
REC opinion
Favourable Opinion